Cargando…
Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
In hemophilia A, routine prophylaxis with exogenous factor VIII (FVIII) requires frequent intravenous injections and can lead to the development of anti-FVIII alloantibodies (FVIII inhibitors). To overcome these drawbacks, we screened asymmetric bispecific IgG antibodies to factor IXa (FIXa) and fac...
Autores principales: | Sampei, Zenjiro, Igawa, Tomoyuki, Soeda, Tetsuhiro, Okuyama-Nishida, Yukiko, Moriyama, Chifumi, Wakabayashi, Tetsuya, Tanaka, Eriko, Muto, Atsushi, Kojima, Tetsuo, Kitazawa, Takehisa, Yoshihashi, Kazutaka, Harada, Aya, Funaki, Miho, Haraya, Kenta, Tachibana, Tatsuhiko, Suzuki, Sachiyo, Esaki, Keiko, Nabuchi, Yoshiaki, Hattori, Kunihiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585358/ https://www.ncbi.nlm.nih.gov/pubmed/23468998 http://dx.doi.org/10.1371/journal.pone.0057479 |
Ejemplares similares
-
Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity
por: Sampei, Zenjiro, et al.
Publicado: (2014) -
Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
por: Kitazawa, Takehisa, et al.
Publicado: (2017) -
Efficient production of bispecific antibody by FAST-Ig(TM) and its application to NXT007 for the treatment of hemophilia A
por: Koga, Hikaru, et al.
Publicado: (2023) -
Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody
por: Sampei, Zenjiro, et al.
Publicado: (2018) -
Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro
por: Noguchi-Sasaki, Mariko, et al.
Publicado: (2018)